Javascript must be enabled to continue!
SYNTHETIC BIOLOGY AND ITS POTENTIAL IN U.S. MEDICAL THERAPEUTICS: A COMPREHENSIVE REVIEW: EXPLORING THE CUTTING-EDGE INTERSECTIONS OF BIOLOGY AND ENGINEERING IN DRUG DEVELOPMENT AND TREATMENTS
View through CrossRef
This study provides a comprehensive review of the cutting-edge intersections of biology and engineering in the realm of medical therapeutics, focusing on the advancements and applications of synthetic biology. The main objectives were to explore the historical evolution, define the scope, and analyze the current state-of-the-art in synthetic biology, particularly in drug development and treatment strategies. The methodology employed a systematic literature review and content analysis, utilizing a range of academic databases to gather relevant peer-reviewed articles published between 2013 and 2023. Key findings revealED that synthetic biology, through the integration of engineering principles and biological systems, has led to significant innovations in medical therapeutics. These include the development of novel drug delivery systems, targeted therapies, and personalized medicine approaches. The study highlights the challenges and limitations in current synthetic biology approaches, such as ethical concerns, regulatory hurdles, and the need for interdisciplinary collaboration. The future landscape of synthetic biology in medicine is marked by both challenges and prospects. The field holds immense potential for addressing complex diseases and enhancing healthcare delivery, yet faces significant challenges in ethical considerations and regulatory frameworks. Strategic recommendations are provided for researchers, industry leaders, and policymakers, emphasizing the need for continuous innovation, ethical applications, and comprehensive regulatory strategies. Finally, synthetic biology stands as a transformative force in medical therapeutics, with the potential to revolutionize healthcare. Future research should focus on overcoming current limitations and exploring new applications, ensuring the field's continued advancement and contribution to global healthcare.
Keywords: Synthetic Biology, Medical Therapeutics, Drug Development, Bioengineering.
Title: SYNTHETIC BIOLOGY AND ITS POTENTIAL IN U.S. MEDICAL THERAPEUTICS: A COMPREHENSIVE REVIEW: EXPLORING THE CUTTING-EDGE INTERSECTIONS OF BIOLOGY AND ENGINEERING IN DRUG DEVELOPMENT AND TREATMENTS
Description:
This study provides a comprehensive review of the cutting-edge intersections of biology and engineering in the realm of medical therapeutics, focusing on the advancements and applications of synthetic biology.
The main objectives were to explore the historical evolution, define the scope, and analyze the current state-of-the-art in synthetic biology, particularly in drug development and treatment strategies.
The methodology employed a systematic literature review and content analysis, utilizing a range of academic databases to gather relevant peer-reviewed articles published between 2013 and 2023.
Key findings revealED that synthetic biology, through the integration of engineering principles and biological systems, has led to significant innovations in medical therapeutics.
These include the development of novel drug delivery systems, targeted therapies, and personalized medicine approaches.
The study highlights the challenges and limitations in current synthetic biology approaches, such as ethical concerns, regulatory hurdles, and the need for interdisciplinary collaboration.
The future landscape of synthetic biology in medicine is marked by both challenges and prospects.
The field holds immense potential for addressing complex diseases and enhancing healthcare delivery, yet faces significant challenges in ethical considerations and regulatory frameworks.
Strategic recommendations are provided for researchers, industry leaders, and policymakers, emphasizing the need for continuous innovation, ethical applications, and comprehensive regulatory strategies.
Finally, synthetic biology stands as a transformative force in medical therapeutics, with the potential to revolutionize healthcare.
Future research should focus on overcoming current limitations and exploring new applications, ensuring the field's continued advancement and contribution to global healthcare.
Keywords: Synthetic Biology, Medical Therapeutics, Drug Development, Bioengineering.
Related Results
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
619. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Epetraborole Dose Selection for the Treatment of Patients with Mycobacterium avium Complex (MAC) Lung Disease
Abstract
Background
Epetraborole (EBO) is an orally available, bacterial leucyl transfer RNA synthetase inhibitor that concentra...
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baum
Abstract
Background
SUL-DUR is a β-lactam/β-lactamase inhibitor combination in development for the treatment of ABC infections, ...
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
Abstract
Background
Epetraborole (EBO), an orally available bacterial leucyl transfer RNA synthetase inhibitor with potent activ...
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
592. Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA)
Abstract
Background
Given the increasing prevalence of non-albicans Candida species, including C. glabrata and C. auris, which h...
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
Selection of Injectable Drug Product Composition using Machine Learning Models (Preprint)
BACKGROUND
As of July 2020, a Web of Science search of “machine learning (ML)” nested within the search of “pharmacokinetics or pharmacodynamics” yielded over 100...
Magic graphs
Magic graphs
DE LA TESIS<br/>Si un graf G admet un etiquetament super edge magic, aleshores G es diu que és un graf super edge màgic. La tesis està principalment enfocada a l'estudi del c...
Cutting Characteristics of Direct Milling of Cemented Tungsten Carbides Using Diamond-Coated Carbide End Mills with Untreated and Treated Cutting Edge
Cutting Characteristics of Direct Milling of Cemented Tungsten Carbides Using Diamond-Coated Carbide End Mills with Untreated and Treated Cutting Edge
This study investigates the cutting characteristics of direct milling of cemented tungsten carbides performed using a diamond-coated carbide end mill. The diamond-coated carbide en...
Study on cutting force of ultrasonic cutting disc cutter for Nomex honeycomb material
Study on cutting force of ultrasonic cutting disc cutter for Nomex honeycomb material
Abstract
To systematically investigate the specific factors influencing cutting force variations in ultrasonic cutting of Nomex honeycomb materials with disc cutters, a com...

